<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZYDELIG- idelalisib tablet, film coated </strong><br>Gilead Sciences, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ZYDELIG safely and effectively. See full prescribing information for ZYDELIG.
 <br><br><br><br>
ZYDELIG® (idelalisib) tablets, for oral use
 <br><br>
Initial U.S. Approval: 2014
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">INTESTINAL PERFORATION</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig. (
           
   
      <a href="#S5.1">5.1</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and/or serious and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> occurred in 14% of Zydelig-treated patients. Monitor for the development of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Interrupt and then reduce or discontinue Zydelig. (
           
   
      <a href="#S5.2">5.2</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> can occur in Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig. (
           
   
      <a href="#S5.3">5.3</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig if <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> is suspected.  (
           
   
      <a href="#S5.4">5.4</a>)
          
  
     </span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">INTESTINAL PERFORATION</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig. (
           
   
      <a href="#S5.1">5.1</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and/or serious and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> occurred in 14% of Zydelig-treated patients. Monitor for the development of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Interrupt and then reduce or discontinue Zydelig. (
           
   
      <a href="#S5.2">5.2</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> can occur in Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig. (
           
   
      <a href="#S5.3">5.3</a>)
          
  
     </span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig if <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> is suspected.  (
           
   
      <a href="#S5.4">5.4</a>)
          
  
     </span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Zydelig is a kinase inhibitor indicated for the treatment of patients with: </p>
<ul>
<li>Relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. (
          
  
     <a href="#S1.1">1.1</a>)
         
 
    </li>
<li>Relapsed follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (FL) in patients who have received at least two prior systemic therapies. (
          
  
     <a href="#S1.2">1.2</a>)
         
 
    </li>
<li>Relapsed small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span> (SLL) in patients who have received at least two prior systemic therapies. (
          
  
     <a href="#S1.3">1.3</a>)
         
 
    </li>
</ul>
<p class="Highlighta">Accelerated approval was granted for FL and SLL based on overall response rate. Improvement in patient survival or disease related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.  </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Recommended starting dose: 150 mg orally, twice daily. (
         
 
    <a href="#S2.1">2.1</a>)
        

    </p></div>
<div></div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 150 mg, 100 mg. (
         
 
    <a href="#S3">3</a>)
        

    </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>. (
         
 
    <a href="#S4">4</a>)
        

    </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig. (
          
  
     <a href="#S5.5">5.5</a>)
         
 
    </li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>: Monitor patients for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and discontinue Zydelig. (
          
  
     <a href="#S5.6">5.6</a>)
         
 
    </li>
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: monitor blood counts. (
          
  
     <a href="#S5.7">5.7</a>) 
         
 
    </li>
<li>Embryo-fetal toxicity: may cause fetal harm. Advise women of potential risk to a fetus and to avoid pregnancy while taking Zydelig. (
          
  
     <a href="#S5.8">5.8</a>)
         
 
    </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence ≥20%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (
         
 
    <a href="#S6.1">6.1</a>).
        

    </p>
<p class="Highlighta">The most common laboratory abnormalities (incidence ≥30%) are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, ALT  elevations, and AST elevations (
         
 
    <a href="#S6.1">6.1</a>). 
        

    </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CYP3A inducers: Avoid coadministration of strong CYP3A inducers with Zydelig. (
          
  
     <a href="#S7.1">7.1</a>)
         
 
    </li>
<li>CYP3A substrates: Avoid coadministration of CYP3A substrates with Zydelig. (
          
  
     <a href="#S7.2">7.2</a>)
         
 
    </li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing mothers: Discontinue drug or nursing. (
         
 
    <a href="#S8.3">8.3</a>)
        

    </p></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>, and  <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">INTESTINAL PERFORATION</span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Relapsed Follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Relapsed Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose </a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Modification </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Hepatotoxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">Intestinal Perforation</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Severe Cutaneous Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Effects of Other Drugs on Zydelig</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Effects of Zydelig on Other Drugs </a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Females of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-11.2" class="toc">13.2	Animal Pharmacology and/or Toxicology</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Relapsed Follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></a></h2>
<h2><a href="#section-12.3" class="toc">14.3	Relapsed Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span></a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1>WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">COLITIS</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span>, and  <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">INTESTINAL PERFORATION</span></h1>
<ul>
<li><span class="Bold">Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients. Monitor hepatic function prior to and during treatment. Interrupt and then reduce or discontinue Zydelig as recommended 
         
   
    <span class="Italics">[see 
          
    
     <a href="#S2.2">Dosage and Administration (2.2)</a>, 
          
    
     <a href="#S5.1">Warnings and Precautions (5.1)</a>].
         
   
    </span></span></li>
<li><span class="Bold">Fatal and/or serious and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> occurred in 14% of Zydelig-treated patients. Monitor for the development of severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Interrupt and then reduce or discontinue Zydelig as recommended 
         
   
    <span class="Italics">[see 
          
    
     <a href="#S2.2">Dosage and Administration (2.2)</a>, 
          
    
     <a href="#S5.2">Warnings and Precautions (5.2)</a>].
         
   
    </span></span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> can occur in Zydelig-treated patients. Monitor for pulmonary symptoms and bilateral interstitial infiltrates. Interrupt or discontinue Zydelig as recommended 
         
   
    <span class="Italics">[see 
          
    
     <a href="#S2.2">Dosage and Administration (2.2)</a>, 
          
    
     <a href="#S5.3">Warnings and Precautions (5.3)</a>].
         
   
    </span></span></li>
<li><span class="Bold">Fatal and serious <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> can occur in Zydelig-treated patients across clinical trials. Discontinue Zydelig for <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> 
         
   
    <span class="Italics">[see 
          
    
     <a href="#S5.4">Warnings and Precautions (5.4)</a>].
         
   
    </span></span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></h2>
<p class="First">Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">chronic lymphocytic leukemia</span> (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Relapsed Follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (FL) who have received at least two prior systemic therapies.</p>
<p>Accelerated approval was granted for this indication based on Overall Response Rate 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S14.2">Clinical Studies (14.2)</a>].
         
 
  </span> An improvement in patient survival or disease related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
        

 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Relapsed Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span></h2>
<p class="First">Zydelig is indicated for the treatment of patients with relapsed small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span> (SLL) who have received at least two prior systemic therapies.</p>
<p>Accelerated approval was granted for this indication based on Overall Response Rate 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S14.3">Clinical Studies (14.3)</a>].
         
 
  </span> An improvement in patient survival or disease related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
        

 </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose </h2>
<p class="First">The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily.</p>
<p>Zydelig can be taken with or without food. Tablets should be swallowed whole.</p>
<p>Continue treatment until disease progression or unacceptable toxicity. The optimal and safe dosing regimen for patients who receive treatment longer than several months is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Modification </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First">See the table below for dose modification instructions for specific toxicities related to Zydelig. For other severe or life-threatening toxicities related to Zydelig, withhold drug until toxicity is resolved. If resuming Zydelig after interruption for other severe or life-threatening toxicities, reduce the dose to 100 mg twice daily. Recurrence of other severe or life-threatening Zydelig-related toxicity upon rechallenge should result in permanent discontinuation of Zydelig.</p>
<table width="80%">
<caption><span>Table 1 	Dose Modifications for Toxicities Due to Zydelig</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></th>
<th class="Rrule" align="center" colspan="3">Any symptomatic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> </th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">Abbreviations: ALT, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>; AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>; BID, twice daily; ULN, upper limit of normal</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Moderate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: increase of 4–6 stools per day over baseline; severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: increase of ≥7 stools per day over baseline.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center" colspan="3">Discontinue Zydelig in patients with any severity of symptomatic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">ALT/AST</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;3–5 × ULN</span></span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;5–20 × ULN</span></span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;20 × ULN</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center">Maintain Zydelig dose. Monitor at least weekly until ≤1 × ULN.</td>
<td class="Botrule Rrule" align="center">Withhold Zydelig.
              
    
     <br>Monitor at least weekly until ALT/AST are ≤1 × ULN, then may resume Zydelig at 100 mg BID.
             
   
    </td>
<td class="Botrule Rrule" align="center">Discontinue Zydelig permanently.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">Bilirubin</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;1.5–3 × ULN</span></span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;3–10 × ULN</span></span></td>
<td class="Botrule Rrule" align="center"><span class="Bold"><span class="Underline">&gt;10 × ULN</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center">Maintain Zydelig dose. Monitor at least weekly until ≤1 × ULN.</td>
<td class="Botrule Rrule" align="center">Withhold Zydelig. Monitor at least weekly until bilirubin  is ≤1 × ULN, then may resume Zydelig at 100 mg BID.</td>
<td class="Botrule Rrule" align="center">Discontinue Zydelig  permanently.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
               
     
      <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Moderate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or hospitalization</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Life-threatening <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center">Maintain Zydelig dose. Monitor at least weekly until resolved.</td>
<td class="Botrule Rrule" align="center"> Withhold Zydelig. Monitor at least weekly until resolved, then may resume Zydelig at 100 mg BID.</td>
<td class="Botrule Rrule" align="center">Discontinue Zydelig permanently.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">ANC 1.0 to &lt;1.5 Gi/L</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">ANC 0.5 to &lt;1.0 Gi/L</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">ANC &lt;0.5 Gi/L</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center">Maintain Zydelig dose.</td>
<td class="Botrule Rrule" align="center">Maintain Zydelig dose. Monitor ANC at least weekly.</td>
<td class="Botrule Rrule" align="center">Interrupt Zydelig. Monitor ANC at least weekly until ANC ≥0.5 Gi/L, then may resume Zydelig at 100 mg BID. </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Platelets 50 to &lt;75 Gi/L</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Platelets 25 to &lt;50 Gi/L</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold"><span class="Underline">Platelets &lt;25 Gi/L</span></span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center">Maintain Zydelig dose.</td>
<td class="Rrule" align="center">Maintain Zydelig dose.  Monitor platelet counts at least weekly. </td>
<td class="Rrule" align="center">Interrupt Zydelig. Monitor platelet count at least weekly. May resume Zydelig at 100 mg BID when platelets ≥25 Gi/L.</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">150 mg tablets: pink, oval-shaped, film-coated tablet debossed with "GSI" on one side and "150" on the other side.</p>
<p>100 mg tablets: orange, oval-shaped, film-coated tablet debossed with "GSI" on one side and "100" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">History of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Hepatotoxicity</h2>
<p class="First">Fatal and/or serious hepatotoxicity occurred in 14% of patients treated with Zydelig. Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S6.1">Adverse Reactions (6.1)</a>].
         
 
  </span> These findings were generally observed within the first 12 weeks of treatment and were reversible with dose interruption. After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations. Discontinue Zydelig for recurrent hepatotoxicity.
        

 </p>
<p>Avoid concurrent use of Zydelig with other drugs that may cause liver toxicity.</p>
<p>Monitor ALT and AST in all patients every 2 weeks for the first 3 months of treatment, every 4 weeks for the next 3 months, then every 1 to 3 months thereafter. Monitor weekly for liver toxicity if the ALT or AST rises above 3 times the upper limit of normal until resolved. Withhold Zydelig if the ALT or AST is greater than 5 times the upper limit of normal, and continue to monitor AST, ALT and total bilirubin weekly until the abnormality is resolved  
         
 
  <span class="Italics">[see 
          
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (Grade 3 or higher) occurred in 14% of Zydelig-treated patients across clinical trials 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S6.1">Adverse Reactions (6.1)</a>].
         
 
  </span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> can occur at any time. Avoid concurrent use of Zydelig and other drugs that cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> due to Zydelig responds poorly to antimotility agents. Median time to resolution ranged between 1 week and 1 month across trials, following interruption of Zydelig therapy and in some instances, use of corticosteroids 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></h2>
<p class="First">Fatal and serious <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> occurred in patients treated with Zydelig. Patients taking Zydelig who present with pulmonary symptoms such as <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, interstitial infiltrates on a radiologic exam, or a decline by more than 5% in oxygen saturation should be evaluated for <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>. If <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> is suspected, interrupt Zydelig until the etiology of the pulmonary symptoms has been determined. Patients with <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> thought to be caused by Zydelig have been treated with discontinuation of Zydelig and administration of corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">Intestinal Perforation</span></h2>
<p class="First">Fatal and serious <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> occurred in Zydelig-treated patients. At the time of perforation, some patients had moderate to severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Advise patients to promptly report any new or worsening <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Discontinue Zydelig permanently in patients who experience <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Severe Cutaneous Reactions</h2>
<p class="First">One case of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) occurred in a study of Zydelig in combination with rituximab and bendamustine. Other severe or life-threatening (Grade ≥3) cutaneous reactions, including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">dermatitis exfoliative</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, have been reported in Zydelig-treated patients. Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported in patients on Zydelig.  In patients who develop serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, discontinue Zydelig permanently and institute appropriate supportive measures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></h2>
<p class="First">Treatment-emergent Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 31% of Zydelig-treated patients across clinical trials 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S6.1">Adverse Reactions (6.1)</a>].
         
 
  </span> Monitor blood counts at least every two weeks for the first 3 months of therapy, and at least weekly in patients while neutrophil counts are less than 1.0 Gi/L 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Embryo-fetal Toxicity</h2>
<p class="First">Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman. Idelalisib is teratogenic in rats, at systemic exposures 12 times those reported in patients at the recommended dose of 150 mg twice daily. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S8.1">Use in Specific Populations (8.1)</a>].
         
 
  </span></p>
<p>Advise females of reproductive potential to avoid becoming pregnant while taking Zydelig. If contraceptive methods are being considered, use effective contraception during treatment, and for at least 1 month after the last dose of Zydelig 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S8.6">Use in Specific Populations (8.6)</a>].
         
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions have been associated with Zydelig in clinical trials and are discussed in greater detail in other sections of the prescribing information.</p>
<ul>
<li>Hepatotoxicity 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.1">Warnings and Precautions (5.1)</a>]
        
  
   </span>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span> 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.2">Warnings and Precautions (5.2)</a>]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span> 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.3">Warnings and Precautions (5.3)</a>]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">Intestinal Perforation</span> 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.4">Warnings and Precautions (5.4)</a>]
        
  
   </span>
</li>
<li>Severe Cutaneous Reactions 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.5">Warnings and Precautions (5.5)</a>]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.6">Warnings and Precautions (5.6)</a>]
        
  
   </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> 
        
  
   <span class="Italics">[see 
         
   
    <a href="#S5.7">Warnings and Precautions (5.7)</a>]
        
  
   </span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Summary of Clinical Trials in <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></span></span></p>
<p>The safety data reflect subject exposure to Zydelig from Study 1, in which 218 subjects with relapsed CLL received up to 8 doses of rituximab with or without Zydelig 150 mg twice daily. The median duration of exposure to Zydelig was 5 months.</p>
<p>Serious adverse reactions were reported in 54 (49%) subjects treated with Zydelig + rituximab. The most frequent (≥2%) serious adverse reactions reported for subjects treated with Zydelig were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (17%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (9%), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (8%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (5%) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%). Adverse reactions that led to discontinuation of Zydelig occurred in 11 (10%) subjects. The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Thirty-nine subjects (35%) had dose interruptions and sixteen subjects (15%) had dose reductions due to adverse reactions or laboratory abnormalities. The most common reasons for dose reductions were elevated transaminases, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Table 2 and Table 3 summarize common adverse reactions and laboratory abnormalities reported for Zydelig + rituximab and placebo + rituximab arms.</p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2 	Adverse Reactions Reported in ≥5% of CLL Patients and Occurred at ≥2% Higher Incidence in Subjects Receiving Zydelig </span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th align="left" colspan="2">Zydelig + R
              
    
     <br>N=110 (%)
             
   
    </th>
<th class="Lrule Rrule" align="left" colspan="2">Placebo + R
              
    
     <br>N=108 (%)
             
   
    </th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left" valign="middle">Adverse Reaction</th>
<th class="Rrule" align="left" valign="middle">Any Grade</th>
<th class="Rrule" align="left" valign="middle">Grade ≥3</th>
<th class="Rrule" align="left" valign="middle">Any Grade</th>
<th class="Rrule" align="left" valign="middle">Grade ≥3</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">R: rituximab</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> includes the following preferred terms:  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> includes the following preferred terms: <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">dermatitis exfoliative</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> includes the terms: <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystis jiroveci pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4112820" conceptname="Legionella pneumonia">pneumonia legionella</span>, <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span> pseudomonal, <span class="product-label-link" type="condition" conceptid="4049965" conceptname="Fungal pneumonia">pneumonia fungal</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span> bacterial.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> includes the terms: <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, <span class="product-label-link" type="condition" conceptid="40484176" conceptname="Neutropenic sepsis">neutropenic sepsis</span>, and <span class="product-label-link" type="condition" conceptid="4029281" conceptname="Sepsis syndrome">sepsis syndrome</span>.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td class="Rrule" align="left">28 (25)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">23 (21)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>  </td>
<td class="Rrule" align="left">14 (13)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">9 (8)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 
              
    
     <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="left">23 (21)</td>
<td class="Rrule" align="left">6 (5)</td>
<td class="Rrule" align="left">17 (16)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span></td>
<td class="Rrule" align="left">7 (6)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">1 (1)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> </td>
<td class="Rrule" align="left">7 (6)</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td class="Rrule" align="left">11 (10)</td>
<td class="Rrule" align="left">1 (1)</td>
<td class="Rrule" align="left">5 (5)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">General disorders and administration site conditions</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></td>
<td class="Rrule" align="left">38 (35)</td>
<td class="Rrule" align="left">3 (3)</td>
<td class="Rrule" align="left">18 (17)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></td>
<td class="Rrule" align="left">23 (21)</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">17 (16)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="left">8 (7)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Skin and subcutaneous tissue disorders</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> 
              
    
     <a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td class="Rrule" align="left">20 (18)</td>
<td class="Rrule" align="left">4 (4)</td>
<td class="Rrule" align="left">7 (6)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> 
              
    
     <a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td class="Rrule" align="left">25 (23)</td>
<td class="Rrule" align="left">18 (16)</td>
<td class="Rrule" align="left">19 (18)</td>
<td class="Rrule" align="left">14 (13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span></td>
<td class="Rrule" align="left">6 (5)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> 
              
    
     <a name="footnote-reference-5" href="#footnote-5" class="Sup">§</a>
</td>
<td class="Rrule" align="left">9 (8)</td>
<td class="Rrule" align="left">8 (7)</td>
<td class="Rrule" align="left">4 (4)</td>
<td class="Rrule" align="left">4 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> </td>
<td class="Rrule" align="left">7 (6)</td>
<td class="Rrule" align="left">1 (1)</td>
<td class="Rrule" align="left">3 (3)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></td>
<td class="Rrule" align="left">9 (8)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">4 (4)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></td>
<td class="Rrule" align="left">6 (5)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">3 (3)</td>
<td class="Rrule" align="left">2 (2)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td></tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></td>
<td class="Rrule" align="left">8 (7)</td>
<td class="Rrule" align="left">1 (1)</td>
<td class="Rrule" align="left">4 (4)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
</tbody>
</table>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 	Treatment-emergent Laboratory Abnormalities Reported in ≥10% of CLL Patients Occurring at a ≥5% Higher Incidence in Subjects Receiving Zydelig </span></caption>
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th align="left" colspan="2">Zydelig + R
              
    
     <br>N=110 (%)
             
   
    </th>
<th class="Lrule Rrule" align="left" colspan="2">Placebo + R
              
    
     <br>N=108 (%)
             
   
    </th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left" valign="middle">Laboratory Parameter</th>
<th class="Rrule" align="left" valign="middle">Any Grade</th>
<th class="Rrule" align="left" valign="middle">Grade 3–4</th>
<th class="Rrule" align="left" valign="middle">Any Grade</th>
<th class="Rrule" align="left" valign="middle">Grade 3–4</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">Grades were obtained per CTCAE version 4.03.
              
    
     <br>R: rituximab
             
   
    </td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5">Hematology abnormalities</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  neutrophil count decreased</td>
<td class="Rrule" align="left">66 (60)</td>
<td class="Rrule" align="left">41 (37)</td>
<td class="Rrule" align="left">55 (51)</td>
<td class="Rrule" align="left">29 (27)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  lymphocyte count decreased</td>
<td class="Rrule" align="left">22 (20)</td>
<td class="Rrule" align="left">10 (9)</td>
<td class="Rrule" align="left">13 (12)</td>
<td class="Rrule" align="left">4 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  lymphocyte count increased</td>
<td class="Rrule" align="left">27 (25)</td>
<td class="Rrule" align="left">20 (18)</td>
<td class="Rrule" align="left">10 (9)</td>
<td class="Rrule" align="left">5 (5)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Serum chemistry abnormalities</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ALT increased</td>
<td class="Rrule" align="left">38 (35)</td>
<td class="Rrule" align="left">9 (8)</td>
<td class="Rrule" align="left">11 (10)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  AST increased</td>
<td class="Rrule" align="left">27 (25)</td>
<td class="Rrule" align="left">6 (5)</td>
<td class="Rrule" align="left">15 (14)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">GGT increased</span></td>
<td class="Rrule" align="left">29 (26)</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">15 (14)</td>
<td class="Rrule" align="left">3 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  triglycerides (<span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>)</td>
<td class="Rrule" align="left">62 (56)</td>
<td class="Rrule" align="left">3 (3)</td>
<td class="Rrule" align="left">37 (34)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span></td>
<td class="Rrule" align="left">59 (54)</td>
<td class="Rrule" align="left">8 (7)</td>
<td class="Rrule" align="left">50 (46)</td>
<td class="Rrule" align="left">2 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span></td>
<td class="Rrule" align="left">12 (11)</td>
<td class="Rrule" align="left">0</td>
<td class="Rrule" align="left">5 (5)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span></td>
<td class="Rrule" align="left">22 (20)</td>
<td class="Rrule" align="left">2 (2)</td>
<td class="Rrule" align="left">16 (15)</td>
<td class="Rrule" align="left">7 (6)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Summary of Clinical Trials in Indolent Non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></span></p>
<p>The safety data reflect exposure to Zydelig in 146 adults with indolent non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> treated with Zydelig 150 mg twice daily in clinical trials. The median duration of exposure was 6.1 months (range 0.3 to 26.4 months).</p>
<p>Serious adverse reactions were reported in  73 (50%) subjects. The most frequent serious adverse reactions that occurred were <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (15%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (11%), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (9%).</p>
<p>Adverse reactions resulted in interruption or discontinuation for 78 (53%) subjects. The most common reasons for interruption or discontinuations were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (11%), <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (11%), and elevated transaminases (10%).</p>
<p>Table 4 provides the adverse reactions occurring in at least 10% of subjects receiving Zydelig monotherapy, and Table 5 provides the treatment-emergent laboratory abnormalities.</p>
<a name="table4"></a><table width="70%">
<caption><span>Table 4 	Adverse Reactions (≥ 10% of Subjects) in Patients with Indolent non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Treated with Zydelig 150 mg BID</span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Zydelig Monotherapy
              
    
     <br>N=146 (%)
             
   
    </th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Rrule" align="left">Any Grade</th>
<th class="Rrule" align="left">Grade ≥3</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> includes the following preferred terms:  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and <span class="product-label-link" type="condition" conceptid="437915" conceptname="Gastrointestinal mucositis">gastrointestinal inflammation</span>.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> includes the following preferred terms: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, and <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>. </dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> includes the terms: <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">pneumonia aspiration</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">atypical pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span>, <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystis jiroveci pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span>, <span class="product-label-link" type="condition" conceptid="4322625" conceptname="Gangrenous pneumonia">pneumonia necrotizing</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="258785" conceptname="Pneumococcal pneumonia">pneumonia pneumococcal</span>, <span class="product-label-link" type="condition" conceptid="259852" conceptname="Staphylococcal pneumonia">pneumonia staphylococcal</span>, <span class="product-label-link" type="condition" conceptid="261324" conceptname="Pneumonia due to Streptococcus">pneumonia streptococcal</span>, <span class="product-label-link" type="condition" conceptid="252949" conceptname="Cytomegaloviral pneumonia">pneumonia cytomegaloviral</span>, and <span class="product-label-link" type="condition" conceptid="437222" conceptname="Respiratory syncytial virus infection">respiratory syncytial virus infection</span>.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> includes the following preferred terms: <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">dermatitis exfoliative</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> 
              
    
     <a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="left">68 (47)</td>
<td class="Rrule" align="left">20 (14)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td class="Rrule" align="left">42 (29)</td>
<td class="Rrule" align="left">2 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> 
              
    
     <a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="left">38 (26)</td>
<td class="Rrule" align="left">3 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Rrule" align="left">22 (15)</td>
<td class="Rrule" align="left">2 (1)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">General disorders and administration site conditions</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td class="Rrule" align="left">44 (30)</td>
<td class="Rrule" align="left">2 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></td>
<td class="Rrule" align="left">41 (28)</td>
<td class="Rrule" align="left">3 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></td>
<td class="Rrule" align="left">17 (12)</td>
<td class="Rrule" align="left">3 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></td>
<td class="Rrule" align="left">15 (10)</td>
<td class="Rrule" align="left">3 (2)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></td>
<td class="Rrule" align="left">18 (12)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> 
              
    
     <a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="left">37 (25)</td>
<td class="Rrule" align="left">23 (16)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></td>
<td class="Rrule" align="left">42 (29)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
<td class="Rrule" align="left">25 (17)</td>
<td class="Rrule" align="left">6 (4)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Skin and subcutaneous disorders</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> 
              
    
     <a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="left">31 (21)</td>
<td class="Rrule" align="left">4 (3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">night sweats</span></td>
<td class="Rrule" align="left">18 (12)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td class="Rrule" align="left">16 (11)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Metabolism and nutrition disorders</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></td>
<td class="Rrule" align="left">24 (16)</td>
<td class="Rrule" align="left">1 (1)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">Psychiatric disorders</td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></td>
<td class="Rrule" align="left">17 (12)</td>
<td class="Rrule" align="left">0</td>
</tr>
</tbody>
</table>
<a name="table5"></a><table width="80%">
<caption><span>Table 5 	Treatment-emergent Laboratory Abnormalities in Patients with Indolent non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Treated with Zydelig 150 mg BID </span></caption>
<col align="left" valign="top" width="49%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">Zydelig Monotherapy
              
    
     <br>N=146  (%)
             
   
    </th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Laboratory Abnormality</th>
<th class="Rrule" align="left">Any Grade</th>
<th class="Rrule" align="left">Grade 3</th>
<th class="Rrule" align="left">Grade 4</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4">Grades were obtained per CTCAE version 4.03.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Serum chemistry abnormalities</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  ALT increased</td>
<td class="Rrule" align="left">73 (50)</td>
<td class="Rrule" align="left">20 (14)</td>
<td class="Rrule" align="left">7 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  AST increased</td>
<td class="Rrule" align="left">60 (41)</td>
<td class="Rrule" align="left">12 (8)</td>
<td class="Rrule" align="left">6 (4)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4">Hematology abnormalities</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> decreased</td>
<td class="Rrule" align="left">78 (53)</td>
<td class="Rrule" align="left">20 (14)</td>
<td class="Rrule" align="left">16 (11)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span></td>
<td class="Rrule" align="left">41 (28)</td>
<td class="Rrule" align="left">3 (2)</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  platelets decreased</td>
<td class="Rrule" align="left">38 (26)</td>
<td class="Rrule" align="left">4 (3)</td>
<td class="Rrule" align="left">5 (3)</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Effects of Other Drugs on Zydelig</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics">CYP3A Inducers</span></p>
<p>The AUC of idelalisib was reduced by 75% when Zydelig was coadministered with a strong CYP3A inducer. Avoid coadministration of Zydelig with strong CYP3A inducers, such as rifampin, phenytoin, St. John's wort, or carbamazepine 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S12.3">Clinical Pharmacology (12.3)</a>].
           
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Italics">CYP3A Inhibitors</span></p>
<p>The AUC of idelalisib was increased 1.8-fold when Zydelig was coadministered with a strong CYP3A inhibitor 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S12.3">Clinical Pharmacology (12.3)</a>].
           
 
  </span> If patients are taking concomitant strong CYP3A inhibitors, monitor for signs of Zydelig toxicity 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S5">Warnings and Precautions (5)</a>].
           
 
  </span> Follow dose modifications for adverse reactions 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
           
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Effects of Zydelig on Other Drugs </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Italics">CYP3A Substrates</span></p>
<p>Zydelig is a strong CYP3A inhibitor. The AUC of a sensitive CYP3A substrate was increased 5.4-fold when Zydelig was coadministered with a sensitive CYP3A substrate. Avoid coadministration of Zydelig with CYP3A substrates 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S12.3">Clinical Pharmacology (12.3)</a>].
           
 
  </span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category D 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S5.8">Warnings and Precautions (5.8)</a>]
           
 
  </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman. Idelalisib was teratogenic in animals. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>In an embryo-fetal development study, pregnant rats were administered oral doses of idelalisib during the period of organogenesis at 25, 75, and 150 mg/kg/day. Embryo-fetal toxicities were observed at the mid- and high-doses that also resulted in maternal toxicity, based on reductions in maternal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Adverse findings at idelalisib doses ≥ 75 mg/kg/day included decreased fetal weights, external malformations (short tail), and skeletal variations (delayed ossification and/or unossification of the skull, vertebrae, and sternebrae). Additional findings were observed at 150 mg/kg/day dose of idelalisib and included urogenital blood loss, complete resorption, increased post-implantation loss, and malformations (vertebral agenesis with anury, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, and <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>/<span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>). The dose of 75 and 150 mg/kg/day of idelalisib in rats resulted in exposures (AUC) of approximately 12 and 30 times, respectively, the human exposure at the recommended dose of 150 mg twice daily.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether idelalisib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Zydelig, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Zydelig in children less than 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In clinical trials of Zydelig in patients with FL, SLL, and CLL, 131/208 (63%) patients were age 65 and older.  No major differences in effectiveness were observed.   In patients 65 years of age or older with indolent non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> in comparison to younger patients, older patients had a higher incidence of discontinuation due to an adverse reaction (28% vs 20%), higher incidence of serious adverse reactions (64% vs 37%), and higher incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (11% vs 5%). In patients 65 years of age or older with CLL in comparison to younger patients, older patients had a higher incidence of discontinuation due to an adverse reaction (11% vs 5%), higher incidence of serious adverse reactions (51% vs 43%), and higher incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (3% vs 0%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Females of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<p class="First"><span class="Italics">Contraception</span></p>
<p>Zydelig may cause fetal harm when administered during pregnancy. Advise females of reproductive potential to avoid becoming pregnant while taking Zydelig. If contraceptive methods are being considered, use effective contraception while taking Zydelig and for at least one month after taking the last dose of Zydelig. Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking Zydelig 
           
 
  <span class="Italics">[see 
            
  
   <a href="#S8.1">Use in Specific Populations (8.1)</a>].
           
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment of Zydelig is necessary for patients with creatinine clearance (CLcr) ≥ 15 mL/min 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S12.3">Clinical Pharmacology (12.3)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The AUC of idelalisib increased up to 1.7-fold in subjects with ALT or AST or bilirubin greater than the upper limit of normal (ULN) compared to healthy subjects with normal ALT or AST or bilirubin values 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S12.3">Clinical Pharmacology (12.3)</a>].
         
 
  </span> Safety and efficacy data are not available in patients with baseline ALT or AST values greater than 2.5 × ULN or bilirubin values greater than 1.5 × ULN, as these patients were excluded from Studies 1 and 2. Patients with baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be monitored for signs of Zydelig toxicity 
         
 
  <span class="Italics">[see
          
  
   <a href="#S5"> Warnings and Precautions (5)</a>].
         
 
  </span> Follow dose modifications for adverse reactions 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
         
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Idelalisib is an inhibitor of phosphatidylinositol 3-kinase, PI3Kδ.</p>
<p>The chemical name for idelalisib is 5-fluoro-3-phenyl-2-[(1S)-1-(
       
 
  <span class="Italics">9H</span>-purin-6-ylamino)propyl]quinazolin-4(
       
 
  <span class="Italics">3H</span>)-one. It has a molecular formula of C
       
 
  <span class="Sub">22</span>H
       
 
  <span class="Sub">18</span>FN
       
 
  <span class="Sub">7</span>O and a molecular weight of 415.42 g/mol. Idelalisib has the following structural formula:
      

 </p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50&amp;name=zydelig-01.jpg"></div>
<p>Idelalisib is a white to off-white solid with a pH-dependent aqueous solubility ranging from &lt;0.1 mg/mL at pH 5–7 to over 1 mg/mL at pH 2 under ambient conditions.</p>
<p>Zydelig (idelalisib) tablets are for oral administration. Each tablet contains either 100 mg or 150 mg of idelalisib with the following inactive ingredients: microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, magnesium stearate and a tablet coating. The tablet coating consists of polyethylene glycol, talc, polyvinyl alcohol, and titanium dioxide and of FD&amp;C Yellow #6/Sunset Yellow FCF Aluminum Lake (for the 100 mg tablet) and red iron oxide (for the 150 mg tablet).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Idelalisib is an inhibitor of PI3Kδ kinase, which is expressed in normal and malignant B-cells. Idelalisib induced <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> and inhibited proliferation in cell lines derived from malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells with idelalisib resulted in inhibition of chemotaxis and <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span>, and reduced cell viability.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Bold">Electrocardiographic Effects</span></p>
<p>The effect of Zydelig (150 mg and 400 mg) on the QT/QTc interval was evaluated in a placebo- and positive-controlled (moxifloxacin 400 mg) crossover study in 46 healthy subjects. At a dose 2.7 times the maximum recommended dose, Zydelig did not prolong the QT/QTc interval (i.e., not greater than or equal to 10 ms).</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Following oral administration of a single dose of Zydelig in the fasted state, the median T
           
 
  <span class="Sub">max</span> was observed at 1.5 hours.
          

 </p>
<p>Idelalisib exposure increased in a less than dose-proportional manner over a dose range of 50 mg to 350 mg twice daily in the fasted state.</p>
<p>Relative to fasting conditions, the administration of a single dose of Zydelig with a high-fat meal increased idelalisib AUC 1.4-fold. Zydelig can be administered without regard to food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Idelalisib is greater than 84% bound to human plasma proteins with no concentration <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The mean blood-to-plasma ratio was 0.7. The population apparent central volume of distribution at steady state is 23 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Elimination</span></p>
<p>Idelalisib is metabolized to its major metabolite GS-563117 via aldehyde oxidase and CYP3A. GS-563117 is inactive against PI3Kδ in vitro. Idelalisib undergoes minor metabolism by UGT1A4.</p>
<p>The population apparent systemic clearance at steady-state is 14.9 L/hr. The population terminal elimination half-life of idelalisib is 8.2 hours. Following a single dose of 150 mg of [
           
 
  <span class="Sup">14</span>C] idelalisib, 78% and 14% of the radioactivity was excreted in feces and urine, respectively. GS-563117 accounted for 49% of the radioactivity in the urine and 44% in the feces.
          

 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Age, Gender, Race, and Weight </span></span></p>
<p>Population pharmacokinetic analyses indicated that age, gender, race, and weight had no effect on idelalisib exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Pediatric Patients</span></span></p>
<p>The pharmacokinetics of idelalisib has not been studied in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>A pharmacokinetic study following a single dose of 150 mg of Zydelig was performed in healthy subjects and subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr 15 to 29 mL/min). Creatinine clearance had no effect on idelalisib exposure. No dose adjustment is needed for patients with CLcr ≥15 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.4.4"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>A pharmacokinetic study of Zydelig was performed in healthy subjects and subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The geometric mean AUC increased up to 1.7-fold in subjects with ALT or AST or bilirubin values greater than the upper limit of normal (ULN) compared to subjects with normal AST or ALT or bilirubin values. Limited safety and efficacy data are available for patients with baseline AST or ALT greater than 2.5 × ULN or bilirubin greater than 1.5 × ULN, as these patients were excluded from Studies 1 and 2. Patients with baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be monitored for signs of Zydelig toxicity 
             
 
  <span class="Italics">[see 
              
  
   <a href="#BOX">Boxed Warning</a></span> and 
             
 
  <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a>].
             
 
  </span> Follow dose modifications for adverse reactions 
             
 
  <span class="Italics">[see 
              
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
             
 
  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">In Vitro Studies</span></span></p>
<p>Idelalisib is a substrate for aldehyde oxidase, CYP3A, and UGT1A4 in vitro. </p>
<p>Idelalisib inhibits CYP2C8, CYP2C19, CYP3A, and UGT1A1 and GS-563117 inhibits CYP2C8, CYP2C9, CYP2C19, CYP3A and UGT1A1 in vitro. Idelalisib and GS-563117 are not likely to inhibit CYP1A, CYP2B6, and CYP2D6. </p>
<p>Idelalisib induces CYP2B6 and CYP3A4, but does not induce CYP1A2 in vitro. GS-563117 does not induce these enzymes.</p>
<p>Idelalisib and GS-563117 are substrates of P-glycoprotein (P-gp) and BCRP in vitro. Idelalisib is not a substrate of OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. GS-563117 is not a substrate of OATP1B1 or OATP1B3.</p>
<p>Idelalisib inhibits P-gp, OATP1B1, and OATP1B3, and GS-563117 inhibits OATP1B1, OATP1B3 in vitro. Idelalisib is not likely to inhibit BCRP, OCT2, OAT1, or OAT3, and GS-563117 is not likely to inhibit P-gp, BCRP, OCT2, OAT1, or OAT3.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Effect of Other Drugs on Idelalisib</span></span></p>
<p>A single dose of 150 mg of Zydelig was administered alone and after rifampin (a strong CYP3A and P-gp inducer) 600 mg once daily for 8 days in healthy subjects. Rifampin decreased the geometric mean idelalisib AUC by 75% and the geometric mean C
             
 
  <span class="Sub">max</span> by 58%. Avoid coadministration of Zydelig with strong CYP3A and P-gp inducers.
            

 </p>
<p>A single dose of 400 mg of Zydelig was administered alone and after ketoconazole (a strong CYP3A and P-gp inhibitor) 400 mg daily for 4 days in healthy subjects. Ketoconazole increased the geometric mean idelalisib AUC by 1.8-fold. No changes in the geometric mean C
             
 
  <span class="Sub">max</span> were observed. Patients taking concomitant CYP3A inhibitors should be monitored for signs of Zydelig toxicity 
             
 
  <span class="Italics">[see 
              
  
   <a href="#S5">Warnings and Precautions (5)</a>].
             
 
  </span> Follow dose modifications for adverse reactions 
             
 
  <span class="Italics">[see 
              
  
   <a href="#S2.2">Dosage and Administration (2.2)</a>].
             
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.5.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Effect of Idelalisib on Other Drugs</span></span></p>
<p>A single oral dose of midazolam 5 mg was administered alone and after Zydelig 150 mg for 15 doses in healthy subjects. The geometric mean midazolam Cmax increased by 2.4-fold and the geometric mean midazolam AUC increased by 5.4-fold. Avoid coadministration of Zydelig with CYP3A substrates, as Zydelig is a strong CYP3A inhibitor.</p>
<p>A single dose of 10 mg of rosuvastatin (OATP1B1 and OATP1B3 substrate) was administered alone and after Zydelig 150 mg for 12 doses in healthy subjects. No changes in exposure to rosuvastatin were observed.</p>
<p>A single dose of 0.5 mg of digoxin (P-gp substrate) was administered alone and after Zydelig 150 mg for 19 doses in healthy subjects. No changes in exposure to digoxin were observed.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-11"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with idelalisib have not been conducted.</p>
<p>Idelalisib did not induce mutations in the bacterial mutagenesis (Ames) assay and was not clastogenic in the in vitro chromosome aberration assay using human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Idelalisib was genotoxic in males in the in vivo rat micronucleus study at a high dose of 2000 mg/kg.</p>
<p>Idelalisib may impair fertility in humans. In a fertility study, treated male rats (25, 50, or 100 mg/kg/day of idelalisib) were mated with untreated females. Decreased epididymidal and testicular weights were observed at all dose levels and reduced sperm concentration at the mid- and high doses; however, there were no adverse effects on fertility parameters. The low dose in males resulted in an exposure (AUC) that is approximately 50% of the exposure in patients at the recommended dose of 150 mg twice daily.</p>
<p>In a separate fertility study, treated female rats (25, 50, or 100 mg/kg/day of idelalisib) were mated with untreated males. There were no adverse effects on fertility parameters; however, there was a decrease in the number of live embryos at the high dose. The high dose in females resulted in an exposure (AUC) that is approximately 17-fold the exposure in patients at the recommended dose of 150 mg twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>13.2	Animal Pharmacology and/or Toxicology</h2>
<p class="First">Toxicities observed in animals and not reported in patients include cardiac toxicity (<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, and increased heart weight) and pancreatic findings (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and low-incidence acinar degeneration and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>). These findings were observed in Sprague-Dawley rats in toxicology studies at exposures (AUCs) higher than those reported in patients at the recommended dose of 150 mg twice daily. Cardiac <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> was mainly seen in a 28-day study in rats, the other findings were observed in the 13-week and/or 6-month studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Relapsed <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic Lymphocytic Leukemia</span></h2>
<p class="First">Zydelig was evaluated in a randomized, double-blind, placebo-controlled study (Study 1) in 220 subjects with relapsed CLL who required treatment and were unable to tolerate standard chemoimmunotherapy due to coexisting medical conditions, reduced renal function as measured by creatinine clearance &lt;60 mL/min, or NCI CTCAE Grade ≥3 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or Grade ≥3 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> resulting from myelotoxic effects of prior therapy with cytotoxic agents. Subjects were randomized 1:1 to receive 8 doses of rituximab (first dose at 375 mg/m
         
 
  <span class="Sup">2</span>, subsequent doses at 500 mg/m
         
 
  <span class="Sup">2</span> every 2 weeks for 4 infusions and every 4 weeks for an additional 4 infusions) in combination with either an oral placebo twice daily or with Zydelig 150 mg taken twice daily until disease progression or unacceptable toxicity.
        

 </p>
<p>In Study 1, the median age was 71 (range 47, 92) with 78% over 65, 66% were male, and 90% were Caucasian. The median time since diagnosis was 8.5 years. The median number of prior therapies was 3. Nearly all (96%) subjects had received prior anti-CD20 monoclonal antibodies. The most common (&gt;15%) prior regimens were: bendamustine + rituximab (98 subjects, 45%), fludarabine + cyclophosphamide + rituximab (75 subjects, 34%), single-agent rituximab (67 subjects, 31%), fludarabine + rituximab (37 subjects, 17%), and chlorambucil (36 subjects, 16%).</p>
<p>The primary endpoint was progression free survival (PFS), as assessed by an independent review committee (IRC). The trial was stopped for efficacy following the first pre-specified interim analysis. Results of a second interim analysis continued to show a statistically significant improvement for Zydelig + rituximab over placebo + rituximab for the primary endpoint of PFS (HR: 0.18, 95% CI [0.10, 0.32], p &lt; 0.0001).  The efficacy results are shown in Table 6 and the Kaplan-Meier curve for PFS is shown in Figure 1.</p>
<table width="70%">
<caption><span>Table 6	Efficacy Results from Study 1 </span></caption>
<col align="left" valign="top" width="8%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="31%">
<col align="left" valign="top" width="31%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left" colspan="2"></th>
<th class="Rrule" align="left">Zydelig + R
            
    
     <br>n=110
           
   
    </th>
<th class="Rrule" align="left">Placebo + R
            
    
     <br>n=110
           
   
    </th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">R: rituximab; PFS: progression-free survival; NR: not reached</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>The p value for PFS was based on stratified log-rank test.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="Bold">PFS</span></td>
<td class="Botrule Rrule" align="left">Median (months) (95% 	CI)</td>
<td class="Botrule Rrule" align="left">NR (10.7, NR)</td>
<td class="Botrule Rrule" align="left">5.5 (3.8, 7.1)</td>
</tr>
<tr>
<td class="Lrule" align="left"></td>
<td class="Botrule Rrule" align="left">Hazard ratio (95% CI)</td>
<td class="Botrule Rrule" align="center" colspan="2">0.18 (0.10, 0.32)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"></td>
<td class="Botrule Rrule" align="left">P-value</td>
<td class="Botrule Rrule" align="center" colspan="2">&lt; 0.0001 
            
    
     <a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 1 Kaplan-Meier Plot of Study 1 IRC-Assessed PFS</span></p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50&amp;name=zydelig-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Relapsed Follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></h2>
<p class="First">The safety and efficacy of Zydelig in patients with FL was evaluated in a single-arm, multicenter clinical trial which included 72 patients with follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> who had relapsed within 6 months following rituximab and an alkylating agent and had received at least 2 prior treatments. The median age was 62 years (range 33 to 84), 54% were male, and 90% were Caucasian. At enrollment, 92% of patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 4.7 years and the median number of prior treatments was 4 (range 2 to 12). The most common prior combination regimens were R-CHOP (49%), BR (50%), and R-CVP (28%). At baseline, 33% of patients had extranodal involvement and 26% had bone marrow involvement.</p>
<p>Patients received 150 mg of Zydelig orally twice daily until evidence of disease progression or unacceptable toxicity. Tumor response was assessed according to the revised International Working Group response criteria for <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span>. The primary endpoint was Independent Review Committee-assessed overall response rate (ORR). Efficacy results are summarized in Table  7.</p>
<table width="75%">
<caption><span>Table 7 	Overall Response Rate (ORR) and Duration of Response (DOR) in Patients with Relapsed Follicular <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> </span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">N=72</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="2">CI = confidence interval; CR = complete response; PR = partial response</td></tr>
<tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Kaplan-Meier estimate</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">ORR 											</td>
<td class="Rrule" align="left">39 (54%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  95% CI</td>
<td class="Botrule Rrule" align="left">(42, 66%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  CR</td>
<td class="Rrule" align="left">6 (8%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  PR</td>
<td class="Botrule Rrule" align="left">33 (46%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median
            
    
     <a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> DOR, months (range)
           
   
    </td>
<td class="Rrule" align="left">median not evaluable (0.0+, 14.8+)</td>
</tr>
</tbody>
</table>
<p>The median time to response was 1.9 months (range 1.6–8.3).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-12.3"></a><p></p>
<h2>14.3	Relapsed Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span></h2>
<p class="First">The safety and efficacy of Zydelig in patients with SLL was evaluated in a single-arm, multicenter clinical trial which included 26 patients with small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span> who had relapsed within 6 months following rituximab and an alkylating agent and had received at least 2 prior treatments. The median age was 65 years (range 50 to 87), 73% were male, and 81% were Caucasian. At enrollment, 96% of patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 6.7 years and the median number of prior treatments was 4 (range 2 to 9). The most common prior combination regimens were BR (81%), FCR (62%) and R-CHOP (35%). At baseline, 27% of patients had extranodal involvement.</p>
<p>Subjects received 150 mg of Zydelig orally twice daily until evidence of disease progression or unacceptable toxicity. Tumor response was assessed according to the revised International Working Group response criteria for <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span>. The primary endpoint was Independent Review Committee-assessed overall response rate (ORR). Efficacy results are summarized in Table 8.</p>
<table width="75%">
<caption><span>Table 8 	Overall Response Rate (ORR) and Duration of Response (DOR) in Patients with Relapsed Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span> </span></caption>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">N=26</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="2">CI = confidence interval; CR = complete response; PR = partial response</td></tr>
<tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Kaplan-Meier estimate</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">ORR 											</td>
<td class="Rrule" align="left">15 (58%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  95% CI</td>
<td class="Botrule Rrule" align="left">(37, 77%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  CR</td>
<td class="Rrule" align="left">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  PR</td>
<td class="Botrule Rrule" align="left">15 (58%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Median
            
    
     <a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a> DOR, months (range)
           
   
    </td>
<td class="Rrule" align="left">11.9 (0.0+, 14.7+)</td>
</tr>
</tbody>
</table>
<p>The median time to response was 1.9 months (range 1.6–8.3). </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Zydelig tablets supplied as follows:</p>
<table width="75%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Tablet Strength</th>
<th class="Rrule" align="left">Package Configuration</th>
<th class="Rrule" align="left">NDC No.</th>
<th class="Rrule" align="left">Description of Tablet; Debossed on Tablet</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">150 mg</td>
<td class="Rrule" align="left" rowspan="2">High density polyethylene (HDPE) bottle with a polyester fiber coil, capped with a child-resistant closure. Each bottle contains 60 film-coated tablets. </td>
<td class="Rrule" align="left">61958-1702-1</td>
<td class="Rrule" align="left">Oval shaped; pink; "150" on one side and "GSI" on the other side</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">100 mg</td>
<td class="Rrule" align="left">61958-1701-1</td>
<td class="Rrule" align="left">Oval-shaped; orange; "100" on one side and "GSI" on the other side</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<p class="First">Store between 20–30 °C (68–86 °F) with excursions permitted 15–30 ºC (59–86 ºF). </p>
<ul>
<li>Dispense only in original container.</li>
<li>Do not use if seal over bottle opening is broken or missing.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (
       
 
  <a href="#MG">Medication Guide</a>).
      

 </p>
<p>Physicians and health care professionals are advised to discuss the following with patients prior to treatment with Zydelig:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold">Hepatotoxicity</span></p>
<p>Advise patients that Zydelig can cause significant elevations in liver enzymes, and that serial testing of serum liver tests (ALT, AST, and bilirubin) are recommended while taking Zydelig 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.1">Warnings and Precautions (5.1)</a>].
         
 
  </span> Advise patients to report symptoms of liver dysfunction including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
        

 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></span></p>
<p>Advise patients that Zydelig may cause severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> and to notify their healthcare provider immediately if the number of bowel movements in a day increases by six or more 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.2">Warnings and Precautions (5.2)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.3"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold"><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span></span></p>
<p>Advise patients of the possibility of <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, and to report any new or worsening respiratory symptoms including <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.3">Warnings and Precautions (5.3)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.4"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold"><span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">Intestinal Perforation</span> </span></p>
<p>Advise patients of the possibility for <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> and to notify their healthcare provider immediately if they experience severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.4">Warnings and Precautions (5.4)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.5"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold">Severe Cutaneous Reactions</span></p>
<p>Advise patients that Zydelig may cause severe cutaneous reactions and to notify their healthcare provider immediately if they develop a severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.5">Warnings and Precautions (5.5)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.6"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></span></p>
<p>Advise patients that <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> can occur during treatment with Zydelig and to notify their healthcare provider immediately if they experience symptoms of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.6">Warnings and Precautions (5.6)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.7"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p>Advise patients of the need for periodic monitoring of blood counts. Advise patients to notify their healthcare provider immediately if they develop a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.7">Warnings and Precautions (5.7)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.8"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold">Pregnancy and Nursing</span></p>
<p>Advise women of the potential hazard to the fetus and to avoid pregnancy during treatment with Zydelig. If contraceptive methods are being considered, advise to use adequate contraception during therapy and for at least one month after completing therapy. Also advise patients not to breastfeed while taking Zydelig 
         
 
  <span class="Italics">[see 
          
  
   <a href="#S5.8">Warnings and Precautions (5.8)</a>									 and 										
          
  
   <a href="#S8.1">Use in Specific Populations (8.1</a>, 
          
  
   <a href="#S8.3">8.3</a>, and 
          
  
   <a href="#S8.6">8.6)</a>].
         
 
  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.9"></a><p></p>
<p class="First">•    
         
 
  <span class="Bold">Instructions for Taking Zydelig</span></p>
<p>Advise patients to take Zydelig exactly as prescribed and not to change their dose or to stop taking Zydelig unless they are told to do so by their healthcare provider. Zydelig may be taken with or without food. Zydelig tablets should be swallowed whole. Advise patients that if a dose of Zydelig is missed by less than 6 hours, to take the missed dose right away and take the next dose as usual.  If a dose of Zydelig is missed by more than 6 hours, advise patients to wait and take the next dose at the usual time.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Manufactured and distributed by:</p>
<p>Gilead Sciences, Inc.</p>
<p>Foster City, CA 94404</p>
<p>GSI and Zydelig are trademarks or registered trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.</p>
<p>©2014 Gilead Sciences, Inc. All rights reserved.</p>
<p>205858-GS-000-PI </p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ZYDELIG
        
  
   <span class="Sup">®</span> (zye-DEL-ig)
        
  
   <br>(idelalisib) tablets
       
 
  </span></p>
<p>Read this Medication Guide before you start taking Zydelig and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about Zydelig?</span></p>
<p><span class="Bold">Zydelig can cause serious side effects that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including:</span></p>
<ul>
<li>
<span class="Bold">Liver problems.</span> Your doctor will do blood tests before and during your treatment with Zydelig to check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems:
        
  
   <ul>
<li>yellowing of your skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark or brown (tea colored) urine</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the upper right side of your stomach area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> more easily than normal</li>
</ul>
</li>
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is common with Zydelig and can sometimes be severe. Tell your doctor right away if the number of bowel movements you have in a day increases by six or more. Ask your doctor about medicines you can take to treat your <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
       
 
  </li>
<li>
<span class="Bold">Lung or breathing problems. </span>Your doctor may do tests to check your lungs if you have breathing problems during treatment with Zydelig. Tell your doctor right away if you get new or worsening <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>.
       
 
  </li>
<li>
<span class="Bold">Tear in intestinal wall (perforation). </span>Tell your doctor or get medical help right away if you get new or worsening stomach area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
       
 
  </li>
</ul>
<p>If you have any of the above serious side effects during treatment with Zydelig, your doctor may completely stop your treatment, stop your treatment for a period of time, or change your dose of Zydelig.</p>
<p>See "
       
 
  <span class="Bold"><a href="#whatareposs">What are the possible side effects of Zydelig?</a></span>" for more information about side effects.
      

 </p>
<p><span class="Bold">What is Zydelig? </span></p>
<p>Zydelig is a prescription medicine used to treat people with:  </p>
<ul>
<li>
<span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span> (CLL)</span> in combination with rituximab when CLL comes back after prior cancer treatment when rituximab treatment alone may be used due to other health problems.
       
 
  </li>
<li>
<span class="Bold">Follicular B-cell non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (FL)</span> when the disease has come back after treatment with at least two prior medicines.
       
 
  </li>
<li>
<span class="Bold">Small <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">Lymphocytic Lymphoma</span> (SLL)</span> when the disease comes back after treatment with at least two prior medicines.
       
 
  </li>
</ul>
<p>It is not known if Zydelig is safe and effective in children less than 18 years of age.</p>
<p><span class="Bold">What should I tell my doctor before taking Zydelig? Before taking Zydelig, tell your doctor about all of your medical conditions, including if you:</span></p>
<ul>
<li>have liver problems</li>
<li>have lung or breathing problems</li>
<li>are pregnant or plan to become pregnant. Zydelig may harm your unborn baby. Females who are able to become pregnant should use effective birth control (contraception) during treatment with Zydelig and for 1 month after stopping treatment. Talk to your doctor about birth control methods that may be right for you. Tell your doctor right away if you become pregnant during treatment with Zydelig.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if Zydelig passes into your breast milk. You and your doctor should decide if you will take Zydelig or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Zydelig and certain other medicines may affect each other. Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. 
      

 </p>
<p><span class="Bold">How should I take Zydelig? </span></p>
<ul>
<li>Take Zydelig exactly as your doctor tells you to take it.</li>
<li>Your doctor may change your dose of Zydelig or tell you to stop taking Zydelig. Do not change your dose or stop taking Zydelig without first talking to your doctor.</li>
<li>Take Zydelig 2 times a day.</li>
<li>You may take Zydelig with or without food.</li>
<li>Take Zydelig tablets whole.</li>
<li>Do not miss a dose of Zydelig.  If you miss a dose of Zydelig by less than 6 hours, take the missed dose right away. Then take your next dose as usual. If you miss a dose of Zydelig by more than 6 hours, wait and take the next dose of Zydelig at your usual time.</li>
</ul>
<p><span class="Bold">What are the possible side effects of Zydelig?</span></p>
<p>Zydelig can cause serious side effects, including:</p>
<ul>
<li>See 
        
  
   <span class="Bold">"
         
   
    <a href="#whatismost">What is the most important information I should know about Zydelig?</a>"
        
  
   </span>
</li>
<li>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> Tell your doctor if you get any of the following symptoms during treatment with Zydelig:
        
  
   <ul>
<li>painful sores or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> on your skin, lips, or in your mouth</li>
<li>severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> skin</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>.</span> Tell your doctor or get medical help right away if you have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> while taking Zydelig.
       
 
  </li>
<li>
<span class="Bold">Low white blood cell count (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>).</span> Your doctor will check your blood counts regularly during treatment with Zydelig. Tell your doctor right away if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or any signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> while taking Zydelig.
       
 
  </li>
</ul>
<p><span class="Bold">The most common side effects of Zydelig include</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, feeling tired, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, stomach area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.
      

 </p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Zydelig. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Zydelig?</span></p>
<ul>
<li>Store Zydelig between 68°F to 86°F (20°C to 30°C).</li>
<li>Keep Zydelig in its original container.</li>
<li>Do not use Zydelig if the seal over the bottle opening is broken or missing.</li>
</ul>
<p><span class="Bold">Keep Zydelig and all medicines out of reach of children.</span></p>
<p><span class="Bold">General information about Zydelig</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Zydelig for a condition for which it was not prescribed. Do not give Zydelig to other people, even if they have the same symptoms you have. It may harm them. You can ask your doctor or pharmacist for information about Zydelig that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in Zydelig?</span></p>
<p><span class="Bold">Active ingredient</span>: idelalisib
      

 </p>
<p><span class="Bold">Inactive ingredients:</span> microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, and magnesium stearate. 
      

 </p>
<p>The tablet coating contains polyethylene glycol, talc, polyvinyl alcohol, titanium dioxide and FD&amp;C Yellow #6/Sunset Yellow (for the 100 mg tablet) and red iron oxide (for the 150 mg tablet). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404
       
 
  <br>©2014 Gilead Sciences, Inc. All rights reserved
       
 
  <br>For more information, call 1-800-445-3235 or go to www.Zydelig.com.
       
 
  <br>205858-GS-000-MG
      

 </p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.
       
 
  <br>Issued: July 2014
      

 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label</h1>
<p class="First">NDC 61958-
       
 
  <span class="Bold">1701</span>-1
       
 
  <br><span class="Bold">60 tablets</span></p>
<p><span class="Bold">Zydelig
        
  
   <span class="Sup">®</span><br>(idelalisib) Tablets
       
 
  </span></p>
<p class="Bold">100 mg</p>
<p>DISPENSER: Each time Zydelig
       
 
  <span class="Sup">®</span> is dispensed
       
 
  <br>give the patient the attached Medication Guide.
      

 </p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50&amp;name=zydelig-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg Tablet Bottle Label</h1>
<p class="First">NDC 61958-
       
 
  <span class="Bold">1702</span>-1
       
 
  <br><span class="Bold">60 tablets</span></p>
<p><span class="Bold">Zydelig
        
  
   <span class="Sup">®</span><br>(idelalisib) Tablets
       
 
  </span></p>
<p class="Bold">150 mg</p>
<p>DISPENSER: Each time Zydelig
       
 
  <span class="Sup">®</span> is dispensed
       
 
  <br>give the patient the attached Medication Guide.
      

 </p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=efbdafa9-d18c-4e85-b4a2-1e620fc74e50&amp;name=zydelig-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZYDELIG 		
					</strong><br><span class="contentTableReg">idelalisib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61958-1701</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IDELALISIB</strong> (IDELALISIB) </td>
<td class="formItem">IDELALISIB</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSI;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61958-1701-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205858</td>
<td class="formItem">07/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZYDELIG 		
					</strong><br><span class="contentTableReg">idelalisib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61958-1702</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IDELALISIB</strong> (IDELALISIB) </td>
<td class="formItem">IDELALISIB</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GSI;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61958-1702-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA205858</td>
<td class="formItem">07/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Gilead Sciences, Inc.
							(185049848)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1f446523-327b-58ed-e054-00144ff8d46c</div>
<div>Set id: efbdafa9-d18c-4e85-b4a2-1e620fc74e50</div>
<div>Version: 4</div>
<div>Effective Time: 20150908</div>
</div>
</div> <div class="DistributorName">Gilead Sciences, Inc.</div></p>
</body></html>
